GINA 2019: a fundamental change in asthma management: Treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents

Helen K Reddel, J Mark FitzGerald, Eric D Bateman, Leonard B Bacharier, Allan Becker, Guy Brusselle, Roland Buhl, Alvaro A Cruz, Louise Fleming, Hiromasa Inoue, Fanny Wai-San Ko, Jerry A Krishnan, Mark L Levy, Jiangtao Lin, Søren E Pedersen, Aziz Sheikh, Arzu Yorgancioglu, Louis-Philippe Boulet

Research output: Contribution to journalArticlepeer-review

Abstract

GINA no longer recommends treating adults/adolescents with asthma with short-acting bronchodilators alone. Instead, they should receive symptom-driven (in mild asthma) or a daily corticosteroid-containing inhaler, to reduce risk of severe exacerbations. http://bit.ly/310LLzE
In April 2019, the Global Initiative for Asthma (GINA) (box 1) published new recommendations that might be considered the most fundamental change in asthma management in 30 years. The new recommendations follow a decade-long programme of work by GINA, prompted by concerns about the risks and consequences of the long-standing approach of commencing asthma treatment with short-acting β2-agonists (SABA) alone. These initiatives were aimed at obtaining evidence about effective treatment options for mild asthma and providing consistent messaging for patients and clinicians across the spectrum of asthma severity.
Original languageEnglish
JournalEuropean Respiratory Journal
Volume53
Issue number6
DOIs
Publication statusPublished - 27 Jun 2019

Fingerprint Dive into the research topics of 'GINA 2019: a fundamental change in asthma management: Treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents'. Together they form a unique fingerprint.

Cite this